Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Vivoryon Therapeutics (Euronext: VVY) announced management will participate in multiple medical and investor conferences in November 2025.
Key events: ASN Kidney Week 2025 (Houston, Nov 5–9) where Vivoryon presents a late-breaking poster on eGFR and pE-CCL2 correlation from the Phase 2b VIVIAD trial (TH-PO1206) on Nov 6, 10:00 am–12:00 pm CST; 1x1 meetings around Jefferies Global Healthcare Conference (London, Nov 18–20); and Deutsches Eigenkapitalforum (Frankfurt, Nov 24–26).
Attending speakers include Michael Schaeffer, PhD, Frank Weber, MD, and Julia Neugebauer, PhD. Investor meeting requests via IR@vivoryon.com.
Vivoryon Therapeutics (Euronext: VVY) ha annunciato che la direzione parteciperà a diverse conferenze mediche e per investitori a novembre 2025.
Eventi chiave: ASN Kidney Week 2025 (Houston, 5–9 novembre) dove Vivoryon presenterà un poster di late-breaking su eGFR e la correlazione pE-CCL2 dallo studio di fase 2b VIVIAD (TH-PO1206) il 6 novembre, dalle 10:00 alle 12:00 CST; 1x1 meeting in occasione della Jefferies Global Healthcare Conference (Londra, 18–20 novembre); e Deutsches Eigenkapitalforum (Francoforte, 24–26 novembre).
Relatori partecipanti includono Michael Schaeffer, PhD, Frank Weber, MD e Julia Neugebauer, PhD. Richieste di incontri con gli investitori via IR@vivoryon.com.
Vivoryon Therapeutics (Euronext: VVY) anunció que la dirección participará en múltiples conferencias médicas y de inversores en noviembre de 2025.
Eventos clave: ASN Kidney Week 2025 (Houston, 5–9 de noviembre) donde Vivoryon presentará un póster de última hora sobre la correlación eGFR y pE-CCL2 del ensayo de fase 2b VIVIAD (TH-PO1206) el 6 de noviembre, de 10:00 a.m. a 12:00 p.m. CST; reuniones 1x1 alrededor de Jefferies Global Healthcare Conference (Londres, 18–20 de noviembre); y Deutsches Eigenkapitalforum (Fráncfort, 24–26 de noviembre).
Ponentes participantes incluyen Michael Schaeffer, PhD, Frank Weber, MD y Julia Neugebauer, PhD. Solicitudes de reuniones con inversores vía IR@vivoryon.com.
Vivoryon Therapeutics (Euronext: VVY)가 2025년 11월 여러 의학 및 투자자 회의에 경영진이 참석할 예정이라고 발표했습니다.
주요 이벤트: ASN Kidney Week 2025 (휴스턴, 11월 5–9일)에서 Vivoryon은 2상 2b VIVIAD 연구(TH-PO1206)의 eGFR와 pE-CCL2 상관관계에 대한 최신 포스터를 11월 6일 CST 오전 10시–오후 12시 사이에 발표합니다; Jefferies Global Healthcare Conference (런던, 11월 18–20일) 관련 1x1 미팅; 그리고 Deutsches Eigenkapitalforum (프랑크푸르트, 11월 24–26일).
발표 연사로는 Michael Schaeffer, PhD, Frank Weber, MD, Julia Neugebauer, PhD가 포함됩니다. 투자자 미팅 요청은 IR@vivoryon.com으로.
Vivoryon Therapeutics (Euronext : VVY) a annoncé que la direction participera à plusieurs conférences médicales et investisseurs en novembre 2025.
Événements clés : ASN Kidney Week 2025 (Houston, du 5 au 9 novembre) où Vivoryon présentera un poster de dernière minute sur la corrélation eGFR et pE-CCL2 issu de l’essai de phase 2b VIVIAD (TH-PO1206) le 6 novembre, de 10h00 à 12h00 CST ; des réunions 1x1 autour de la Jefferies Global Healthcare Conference (Londres, du 18 au 20 novembre) ; et Deutsches Eigenkapitalforum (Francfort, du 24 au 26 novembre).
Les intervenants participant incluent Michael Schaeffer, PhD, Frank Weber, MD et Julia Neugebauer, PhD. Demandes de rencontres investisseurs via IR@vivoryon.com.
Vivoryon Therapeutics (an der Euronext: VVY) hat bekannt gegeben, dass das Management an mehreren medizinischen und investorenseminaren im November 2025 teilnehmen wird.
Wichtige Termine: ASN Kidney Week 2025 (Houston, 5.–9. November), bei dem Vivoryon einen Late-Breaking-Poster zur eGFR und pE-CCL2-Korrelation aus der Phase-2b-VIVIAD-Studie (TH-PO1206) am 6. November von 10:00 bis 12:00 CST präsentieren wird; 1x1 Meetings rund um die Jefferies Global Healthcare Conference (London, 18.–20. November); und Deutsches Eigenkapitalforum (Frankfurt, 24.–26. November).
Veranstaltende Sprecher sind unter anderem Michael Schaeffer, PhD, Frank Weber, MD und Julia Neugebauer, PhD. Anfragen von Investoren für Meetings über IR@vivoryon.com.
Vivoryon Therapeutics (بورصة يورونكس: VVY) أعلنت أن الإدارة ستشارك في عدة مؤتمرات طبية وفي مؤتمرات مستثمرين في نوفمبر 2025.
الأحداث الرئيسية: ASN Kidney Week 2025 (هيوستن، من 5 إلى 9 نوفمبر) حيث ستقدم Vivoryon ملصقاً حديثاً عن علاقة eGFR و pE-CCL2 من تجربة المرحلة 2b VIVIAD (TH-PO1206) في 6 نوفمبر، من 10:00 صباحاً حتى 12:00 ظهراً بتوقيت CST؛ اجتماعات فردية 1x1 حول Jefferies Global Healthcare Conference (لندن، 18–20 نوفمبر)؛ وDeutsches Eigenkapitalforum (Frankfurt، 24–26 نوفمبر).
المتحدثون المشاركون يشملون Michael Schaeffer, PhD، Frank Weber, MD، وJulia Neugebauer, PhD. طلبات اجتماعات المستثمرين عبر IR@vivoryon.com.
- None.
- None.
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November:
American Society of Nephrology (ASN) Kidney Week 2025
Date: November 5 – 9, 2025
Location: Houston, TX, USA
Title: “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial”
Presentation Time: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm - 7:00 pm CET
Session: Late-Breaking Research Posters
Abstract number/poster details: TH-PO1206
Attendees: Michael Schaeffer, PhD, CBO; Julia Neugebauer, PhD, COO
Link to conference: American Society of Nephrology | Kidney Week - Annual Meeting (2025)
1x1 meetings around the Jefferies Global Healthcare Conference
Date: November 18 – 20, 2025
Location: London, UK
Attendees: Frank Weber, MD, CEO; Julia Neugebauer, PhD, COO
To meet the team contact: IR@vivoryon.com
Deutsches Eigenkapitalforum
Date: November 24 – 26, 2025
Location: Frankfurt/M, Germany
Attendee: Julia Neugebauer, PhD, COO
Link to conference: Deutsches Eigenkapitalforum
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When will Vivoryon (VVY) present VIVIAD Phase 2b data at ASN Kidney Week 2025?
What is the poster topic Vivoryon (VVY) is presenting at ASN Kidney Week 2025?
Who from Vivoryon (VVY) will attend the Jefferies Global Healthcare meetings in London?
How can investors request meetings with Vivoryon (VVY) around the Jefferies conference?
Which Vivoryon (VVY) executive will attend Deutsches Eigenkapitalforum in Frankfurt?
Where and when is ASN Kidney Week 2025 where Vivoryon (VVY) will present?
